Research ArticleArticle
Increasing Treatment in Early Rheumatoid Arthritis Is Not Determined by the Disease Activity Score But by Physician Global Assessment: Results from the CATCH Study
Lonnie Pyne, Vivian P. Bykerk, Gilles Boire, Boulos Haraoui, Carol Hitchon, J. Carter Thorne, Edward C. Keystone, Janet E. Pope for the CATCH Investigators and Janet E. Pope for the CATCH Investigators
The Journal of Rheumatology September 2012, jrheum.120520; DOI: https://doi.org/10.3899/jrheum.120520
Lonnie Pyne
From the Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario; Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario; Department of Rheumatology, Brigham and Women’s Hospital, Harvard University, Boston, Massachusetts, USA; Rheumatology Division, Universite de Sherbrooke, Sherbrooke, Quebec; Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; Southlake Regional Health Centre, Newmarket, Ontario; and the Department of Rheumatology, St. Joseph’s Health Care, London, Ontario, Canada. The CATCH study was supported initially by Amgen Canada Inc. and Pfizer Canada Inc. through an unrestricted research grant, and by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., Abbott Laboratories Ltd., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Lonnie Pyne received the Canadian Rheumatology Association Roche Summer Studentship and JuMP (Joint Motion Program) trainee summer studentship (Canadian Institutes of Health Research NET training grant). L. Pyne, Medical Student, Schulich School of Medicine and Dentistry, University of Western Ontario; V.P. Bykerk, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Department of Rheumatology, Brigham and Women’s Hospital, Harvard University; G. Boire, MD, FRCPC, MSc, Rheumatology Division, Universite de Sherbrooke; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie; C. Hitchon, MD, FRCPC, MSc, Arthritis Centre, University of Manitoba; C. Thorne, MD, FRCPC, FACP, Southlake Regional Health Centre; E.C. Keystone, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto; J.E. Pope, MD, MPH, FRCPC, Schulich School of Medicine and Dentistry, University of Western Ontario, Department of Rheumatology, St. Joseph’s Health Care. Address correspondence to Dr. J.E. Pope, 268 Grosvenor Street, London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca Accepted for publication June 28, 2012.
Vivian P. Bykerk
From the Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario; Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario; Department of Rheumatology, Brigham and Women’s Hospital, Harvard University, Boston, Massachusetts, USA; Rheumatology Division, Universite de Sherbrooke, Sherbrooke, Quebec; Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; Southlake Regional Health Centre, Newmarket, Ontario; and the Department of Rheumatology, St. Joseph’s Health Care, London, Ontario, Canada. The CATCH study was supported initially by Amgen Canada Inc. and Pfizer Canada Inc. through an unrestricted research grant, and by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., Abbott Laboratories Ltd., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Lonnie Pyne received the Canadian Rheumatology Association Roche Summer Studentship and JuMP (Joint Motion Program) trainee summer studentship (Canadian Institutes of Health Research NET training grant). L. Pyne, Medical Student, Schulich School of Medicine and Dentistry, University of Western Ontario; V.P. Bykerk, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Department of Rheumatology, Brigham and Women’s Hospital, Harvard University; G. Boire, MD, FRCPC, MSc, Rheumatology Division, Universite de Sherbrooke; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie; C. Hitchon, MD, FRCPC, MSc, Arthritis Centre, University of Manitoba; C. Thorne, MD, FRCPC, FACP, Southlake Regional Health Centre; E.C. Keystone, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto; J.E. Pope, MD, MPH, FRCPC, Schulich School of Medicine and Dentistry, University of Western Ontario, Department of Rheumatology, St. Joseph’s Health Care. Address correspondence to Dr. J.E. Pope, 268 Grosvenor Street, London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca Accepted for publication June 28, 2012.
Gilles Boire
From the Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario; Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario; Department of Rheumatology, Brigham and Women’s Hospital, Harvard University, Boston, Massachusetts, USA; Rheumatology Division, Universite de Sherbrooke, Sherbrooke, Quebec; Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; Southlake Regional Health Centre, Newmarket, Ontario; and the Department of Rheumatology, St. Joseph’s Health Care, London, Ontario, Canada. The CATCH study was supported initially by Amgen Canada Inc. and Pfizer Canada Inc. through an unrestricted research grant, and by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., Abbott Laboratories Ltd., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Lonnie Pyne received the Canadian Rheumatology Association Roche Summer Studentship and JuMP (Joint Motion Program) trainee summer studentship (Canadian Institutes of Health Research NET training grant). L. Pyne, Medical Student, Schulich School of Medicine and Dentistry, University of Western Ontario; V.P. Bykerk, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Department of Rheumatology, Brigham and Women’s Hospital, Harvard University; G. Boire, MD, FRCPC, MSc, Rheumatology Division, Universite de Sherbrooke; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie; C. Hitchon, MD, FRCPC, MSc, Arthritis Centre, University of Manitoba; C. Thorne, MD, FRCPC, FACP, Southlake Regional Health Centre; E.C. Keystone, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto; J.E. Pope, MD, MPH, FRCPC, Schulich School of Medicine and Dentistry, University of Western Ontario, Department of Rheumatology, St. Joseph’s Health Care. Address correspondence to Dr. J.E. Pope, 268 Grosvenor Street, London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca Accepted for publication June 28, 2012.
Boulos Haraoui
From the Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario; Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario; Department of Rheumatology, Brigham and Women’s Hospital, Harvard University, Boston, Massachusetts, USA; Rheumatology Division, Universite de Sherbrooke, Sherbrooke, Quebec; Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; Southlake Regional Health Centre, Newmarket, Ontario; and the Department of Rheumatology, St. Joseph’s Health Care, London, Ontario, Canada. The CATCH study was supported initially by Amgen Canada Inc. and Pfizer Canada Inc. through an unrestricted research grant, and by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., Abbott Laboratories Ltd., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Lonnie Pyne received the Canadian Rheumatology Association Roche Summer Studentship and JuMP (Joint Motion Program) trainee summer studentship (Canadian Institutes of Health Research NET training grant). L. Pyne, Medical Student, Schulich School of Medicine and Dentistry, University of Western Ontario; V.P. Bykerk, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Department of Rheumatology, Brigham and Women’s Hospital, Harvard University; G. Boire, MD, FRCPC, MSc, Rheumatology Division, Universite de Sherbrooke; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie; C. Hitchon, MD, FRCPC, MSc, Arthritis Centre, University of Manitoba; C. Thorne, MD, FRCPC, FACP, Southlake Regional Health Centre; E.C. Keystone, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto; J.E. Pope, MD, MPH, FRCPC, Schulich School of Medicine and Dentistry, University of Western Ontario, Department of Rheumatology, St. Joseph’s Health Care. Address correspondence to Dr. J.E. Pope, 268 Grosvenor Street, London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca Accepted for publication June 28, 2012.
Carol Hitchon
From the Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario; Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario; Department of Rheumatology, Brigham and Women’s Hospital, Harvard University, Boston, Massachusetts, USA; Rheumatology Division, Universite de Sherbrooke, Sherbrooke, Quebec; Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; Southlake Regional Health Centre, Newmarket, Ontario; and the Department of Rheumatology, St. Joseph’s Health Care, London, Ontario, Canada. The CATCH study was supported initially by Amgen Canada Inc. and Pfizer Canada Inc. through an unrestricted research grant, and by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., Abbott Laboratories Ltd., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Lonnie Pyne received the Canadian Rheumatology Association Roche Summer Studentship and JuMP (Joint Motion Program) trainee summer studentship (Canadian Institutes of Health Research NET training grant). L. Pyne, Medical Student, Schulich School of Medicine and Dentistry, University of Western Ontario; V.P. Bykerk, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Department of Rheumatology, Brigham and Women’s Hospital, Harvard University; G. Boire, MD, FRCPC, MSc, Rheumatology Division, Universite de Sherbrooke; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie; C. Hitchon, MD, FRCPC, MSc, Arthritis Centre, University of Manitoba; C. Thorne, MD, FRCPC, FACP, Southlake Regional Health Centre; E.C. Keystone, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto; J.E. Pope, MD, MPH, FRCPC, Schulich School of Medicine and Dentistry, University of Western Ontario, Department of Rheumatology, St. Joseph’s Health Care. Address correspondence to Dr. J.E. Pope, 268 Grosvenor Street, London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca Accepted for publication June 28, 2012.
J. Carter Thorne
From the Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario; Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario; Department of Rheumatology, Brigham and Women’s Hospital, Harvard University, Boston, Massachusetts, USA; Rheumatology Division, Universite de Sherbrooke, Sherbrooke, Quebec; Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; Southlake Regional Health Centre, Newmarket, Ontario; and the Department of Rheumatology, St. Joseph’s Health Care, London, Ontario, Canada. The CATCH study was supported initially by Amgen Canada Inc. and Pfizer Canada Inc. through an unrestricted research grant, and by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., Abbott Laboratories Ltd., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Lonnie Pyne received the Canadian Rheumatology Association Roche Summer Studentship and JuMP (Joint Motion Program) trainee summer studentship (Canadian Institutes of Health Research NET training grant). L. Pyne, Medical Student, Schulich School of Medicine and Dentistry, University of Western Ontario; V.P. Bykerk, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Department of Rheumatology, Brigham and Women’s Hospital, Harvard University; G. Boire, MD, FRCPC, MSc, Rheumatology Division, Universite de Sherbrooke; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie; C. Hitchon, MD, FRCPC, MSc, Arthritis Centre, University of Manitoba; C. Thorne, MD, FRCPC, FACP, Southlake Regional Health Centre; E.C. Keystone, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto; J.E. Pope, MD, MPH, FRCPC, Schulich School of Medicine and Dentistry, University of Western Ontario, Department of Rheumatology, St. Joseph’s Health Care. Address correspondence to Dr. J.E. Pope, 268 Grosvenor Street, London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca Accepted for publication June 28, 2012.
Edward C. Keystone
From the Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario; Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario; Department of Rheumatology, Brigham and Women’s Hospital, Harvard University, Boston, Massachusetts, USA; Rheumatology Division, Universite de Sherbrooke, Sherbrooke, Quebec; Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; Southlake Regional Health Centre, Newmarket, Ontario; and the Department of Rheumatology, St. Joseph’s Health Care, London, Ontario, Canada. The CATCH study was supported initially by Amgen Canada Inc. and Pfizer Canada Inc. through an unrestricted research grant, and by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., Abbott Laboratories Ltd., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Lonnie Pyne received the Canadian Rheumatology Association Roche Summer Studentship and JuMP (Joint Motion Program) trainee summer studentship (Canadian Institutes of Health Research NET training grant). L. Pyne, Medical Student, Schulich School of Medicine and Dentistry, University of Western Ontario; V.P. Bykerk, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Department of Rheumatology, Brigham and Women’s Hospital, Harvard University; G. Boire, MD, FRCPC, MSc, Rheumatology Division, Universite de Sherbrooke; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie; C. Hitchon, MD, FRCPC, MSc, Arthritis Centre, University of Manitoba; C. Thorne, MD, FRCPC, FACP, Southlake Regional Health Centre; E.C. Keystone, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto; J.E. Pope, MD, MPH, FRCPC, Schulich School of Medicine and Dentistry, University of Western Ontario, Department of Rheumatology, St. Joseph’s Health Care. Address correspondence to Dr. J.E. Pope, 268 Grosvenor Street, London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca Accepted for publication June 28, 2012.
Janet E. Pope
From the Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario; Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario; Department of Rheumatology, Brigham and Women’s Hospital, Harvard University, Boston, Massachusetts, USA; Rheumatology Division, Universite de Sherbrooke, Sherbrooke, Quebec; Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; Southlake Regional Health Centre, Newmarket, Ontario; and the Department of Rheumatology, St. Joseph’s Health Care, London, Ontario, Canada. The CATCH study was supported initially by Amgen Canada Inc. and Pfizer Canada Inc. through an unrestricted research grant, and by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., Abbott Laboratories Ltd., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Lonnie Pyne received the Canadian Rheumatology Association Roche Summer Studentship and JuMP (Joint Motion Program) trainee summer studentship (Canadian Institutes of Health Research NET training grant). L. Pyne, Medical Student, Schulich School of Medicine and Dentistry, University of Western Ontario; V.P. Bykerk, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Department of Rheumatology, Brigham and Women’s Hospital, Harvard University; G. Boire, MD, FRCPC, MSc, Rheumatology Division, Universite de Sherbrooke; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie; C. Hitchon, MD, FRCPC, MSc, Arthritis Centre, University of Manitoba; C. Thorne, MD, FRCPC, FACP, Southlake Regional Health Centre; E.C. Keystone, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto; J.E. Pope, MD, MPH, FRCPC, Schulich School of Medicine and Dentistry, University of Western Ontario, Department of Rheumatology, St. Joseph’s Health Care. Address correspondence to Dr. J.E. Pope, 268 Grosvenor Street, London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca Accepted for publication June 28, 2012.
Janet E. Pope
From the Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario; Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario; Department of Rheumatology, Brigham and Women’s Hospital, Harvard University, Boston, Massachusetts, USA; Rheumatology Division, Universite de Sherbrooke, Sherbrooke, Quebec; Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; Southlake Regional Health Centre, Newmarket, Ontario; and the Department of Rheumatology, St. Joseph’s Health Care, London, Ontario, Canada. The CATCH study was supported initially by Amgen Canada Inc. and Pfizer Canada Inc. through an unrestricted research grant, and by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., Abbott Laboratories Ltd., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Lonnie Pyne received the Canadian Rheumatology Association Roche Summer Studentship and JuMP (Joint Motion Program) trainee summer studentship (Canadian Institutes of Health Research NET training grant). L. Pyne, Medical Student, Schulich School of Medicine and Dentistry, University of Western Ontario; V.P. Bykerk, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto, Department of Rheumatology, Brigham and Women’s Hospital, Harvard University; G. Boire, MD, FRCPC, MSc, Rheumatology Division, Universite de Sherbrooke; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie; C. Hitchon, MD, FRCPC, MSc, Arthritis Centre, University of Manitoba; C. Thorne, MD, FRCPC, FACP, Southlake Regional Health Centre; E.C. Keystone, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto; J.E. Pope, MD, MPH, FRCPC, Schulich School of Medicine and Dentistry, University of Western Ontario, Department of Rheumatology, St. Joseph’s Health Care. Address correspondence to Dr. J.E. Pope, 268 Grosvenor Street, London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca Accepted for publication June 28, 2012.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Increasing Treatment in Early Rheumatoid Arthritis Is Not Determined by the Disease Activity Score But by Physician Global Assessment: Results from the CATCH Study
Lonnie Pyne, Vivian P. Bykerk, Gilles Boire, Boulos Haraoui, Carol Hitchon, J. Carter Thorne, Edward C. Keystone, Janet E. Pope for the CATCH Investigators, Janet E. Pope for the CATCH Investigators
The Journal of Rheumatology Sep 2012, jrheum.120520; DOI: 10.3899/jrheum.120520
Increasing Treatment in Early Rheumatoid Arthritis Is Not Determined by the Disease Activity Score But by Physician Global Assessment: Results from the CATCH Study
Lonnie Pyne, Vivian P. Bykerk, Gilles Boire, Boulos Haraoui, Carol Hitchon, J. Carter Thorne, Edward C. Keystone, Janet E. Pope for the CATCH Investigators, Janet E. Pope for the CATCH Investigators
The Journal of Rheumatology Sep 2012, jrheum.120520; DOI: 10.3899/jrheum.120520